June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Incyte INCY announced that the FDA has extended the review period for the supplemental new drug application (sNDA) for ...

Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about ...

Non-JAK2 mutations, particularly in SRSF2, ASXL1, and IDH2, were independently associated with worse survival outcomes in ...

Israel launches strikes on missile facilities in central Iran: air force Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy ...

MorphoSys has said it will press ahead with regulatory filings for its myelofibrosis drug candidate pelabresib, despite mixed results in a phase 3 trial. The German biotech says it hopes the ...

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquired as part of its $1.9 ...

Even professionals can be confused about the difference between folic acid and folate. Both are forms of an essential vitamin – B9. And both play important roles in key functions of your body.